Qlarant, the US-based healthcare technology company, on Tuesday launched a strategic investment subsidiary, Qlarant Capital, which will fund early-stage healthcare startups.
Initially formed as a quality review service for public healthcare programmes, Qlarant now uses artificial intelligence and predictive modelling to improve business efficiency and cut waste or fraud in government and across industries like healthcare, insurance and transportation.
Qlarant Capital will make early-stage investments, providing $50,000 to $2m per deal while offering assistance in areas such as product development, machine learning engineering, regulatory compliance, sales and marketing.
The unit will be run by Qlarant’s president and chief executive, Ron Forsythe, in collaboration with chief financial officer Dana Fidler and Holly Pu, the company’s vice-president of new product development. It is yet to announce its first deal.
Forsythe said: “With our 50 years’ experience in the healthcare and technology industries, launching Qlarant Capital is a natural extension of our core business.
“We are excited to bring our capital and expertise to selected early-stage startups and to support them building a bright future. We are positioned to be a strategic value-add investor.”
Image courtesy of Qlarant Inc.
